1.	Record Nr.	UNINA9910819023703321
	Titolo	BioWatch PCR assays: building confidence, ensuring reliability / / Committee on PCR Standards for the BioWatch Program, Board on Life Sciences, Division on Earth and Life Studies, Board on Health Sciences Policy, Institute of Medicine, National Research Council and Institute of Medicine of the National Academies
	Pubbl/distr/stampa	Washington, District of Columbia:,: The National Academies Press,, [2015] ©2015
	ISBN	0-309-36725-5 0-309-36723-9
	Edizione	[Abbreviated version.]
	Descrizione fisica	1 online resource (186 p.)
	Soggetti	Bioterrorism - United States - Prevention Polymerase chain reaction Pathogenic microorganisms - Detection - United States United States
	Lingua di pubblicazione	Inglese
	Lingua di pubblicazione Formato	Materiale a stampa
		Materiale a stampa  Monografia
	Formato	Materiale a stampa
	Formato Livello bibliografico	Materiale a stampa  Monografia
	Formato Livello bibliografico Note generali	Materiale a stampa  Monografia  Description based upon print version of record.

of a larger array of disease surveillance, intelligence-gathering, and biomonitoring activities in support of public safety and health. The assays used in the BioWatch system to detect the presence of pathogens in collected samples rely on the technique of polymerase chain reaction (PCR) to sensitively and specifically amplify target nucleic acid sequences. BioWatch PCR Assays evaluates and provides guidance on appropriate standards for the validation and verification of PCR tests and assays in order to ensure that adequate performance data are available to public health and other key decision makers with a sufficient confidence level to facilitate the public health response to a BioWatch Actionable Response. This report discusses principles of performance standards, reviews information from several existing guidance documents and standards that might be applicable to BioWatch, and discusses assay testing efforts that have occurred or are ongoing. BioWatch PCR Assays provides recommendations on general principles and approaches for a performance standard and validation framework to meet BioWatch's mission. The report also considers how developments in technology, particularly in multiplex PCR and nextgeneration sequencing, can contribute to the ability of the BioWatch program to meet current and future challenges. This report has been determined to contain information exempt from disclosure under 5 U.S. C. 552(b). Section 15 of the Federal Advisory Committee Act provides that the National Academies shall make its final report available to the public unless the National Academies determines that the report would disclose matters described in one or more of the exemption provisions under the Freedom of Information Act (FOIA). In such case, the National Academies "shall make public an abbreviated version of the report that does not disclose those matters." This unrestricted, abbreviated version of the report represents, in so far as possible, the committee's findings, recommendations, and other substantive material without disclosing materials described in 5 U.S.C. 552(b)"--Publisher's description.